AbCellera Biologics Inc. (NASDAQ: ABCL)

AbCellera Biologics Inc., a biotechnology company with the ticker symbol ABCL, operates in the global market for solutions that enable the discovery and development of therapeutic antibodies. The company's mission is to bring better antibody drugs to patients faster by solving general problems to catalyze a transformation in how antibody drugs are discovered. AbCellera's business model is capital-efficient and based on partnering, which enables the company to generate a significant competitive advantage in the maturity of its technology and the scale of its operations.

AbCellera's main business activities involve the discovery and development of therapeutic antibodies. The company's integrated engine for accelerated drug discovery is designed to systematically produce therapeutic antibodies that meet the many requirements for proceeding into clinical testing. AbCellera's engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies with higher target-binding specificity and developability than those generated by synthetic methods. Through proprietary immunization strategies and single-cell screening, AbCellera maximizes the search space to generate a wide range of diverse antibodies. The engine integrates expert teams, technology, and facilities with data science and automation to support the optimized workflows necessary to move therapeutic programs from concept through to the clinic.

AbCellera's discovery engine requires interdisciplinary talent, and the company believes it is effective at assembling and integrating strong cross-functional teams. As of December 31, 2